liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients
Aalborg Univ Hosp, Denmark; Aalborg Univ, Denmark.
Lund Univ, Sweden.
Oslo Univ Hosp, Norway.
Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden.
Visa övriga samt affilieringar
2020 (Engelska)Ingår i: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 189, nr 4, s. 661-671Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Non-endemic Burkitt lymphoma (BL) is a rare germinal centre B-cell-derived malignancy with the genetic hallmark of MYC gene translocation and with rapid tumour growth as a distinct clinical feature. To investigate treatment outcomes, loss of lifetime and relapse risk in adult BL patients treated with intensive immunochemotherapy, retrospective clinic-based and population-based lymphoma registries from six countries were used to identify 264 real-world patients. The median age was 47 years and the majority had advanced-stage disease and elevated LDH. Treatment protocols were R-CODOX-M/IVAC (47%), R-hyper-CVAD (16%), DA-EPOCH-R (11%), R-BFM/GMALL (25%) and other (2%) leading to an overall response rate of 89%. The two-year overall survival and event-free survival were 84% and 80% respectively. For patients in complete remission/unconfirmed, the two-year relapse risk was 6% but diminished to 0 center dot 6% for patients reaching 12 months of post-remission event-free survival (pEFS12). The loss of lifetime for pEFS12 patients was 0 center dot 4 (95% CI: -0 center dot 7 to 2) months. In conclusion, real-world outcomes of adult BL are excellent following intensive immunochemotherapy. For pEFS12 patients, the relapse risk was low and life expectancy similar to that of a general population, which is important information for developing meaningful follow-up strategies with increased focus on survivorship and less focus on routine disease surveillance.

Ort, förlag, år, upplaga, sidor
WILEY , 2020. Vol. 189, nr 4, s. 661-671
Nyckelord [en]
Burkitt lymphoma; immunochemotherapy; survival; prognosis; real-world patients
Nationell ämneskategori
Hematologi
Identifikatorer
URN: urn:nbn:se:liu:diva-163706DOI: 10.1111/bjh.16425ISI: 000510759700001PubMedID: 32017050OAI: oai:DiVA.org:liu-163706DiVA, id: diva2:1394315
Anmärkning

Funding Agencies|US National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Danish Cancer SocietyDanish Cancer Society; Danish North Jutland Region

Tillgänglig från: 2020-02-18 Skapad: 2020-02-18 Senast uppdaterad: 2021-05-04

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Sök vidare i DiVA

Av författaren/redaktören
Lagerlöf, Ingemar
Av organisationen
Avdelningen för läkemedelsforskningMedicinska fakulteten
I samma tidskrift
British Journal of Haematology
Hematologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 32 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf